Public Policy Issues in Direct-to-Consumer Advertising of Prescription Drugs
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
In August 1997, the Food and Drug Administration (FDA) announced a reinterpretation of its rules on direct-to-consumer (DTC) advertising, the effect of which was to permit branded broadcast advertisements and therefore to increase the volume of DTC advertising several-fold. A substantial body of research, consisting primarily of consumer surveys, provides the basis for a preliminary assessment of the effects of DTC advertisements. The FDA's own assessment, that DTC advertisements can provide substantial benefits and do not appear to cause substantial harm, is consistent with survey and other data. Direct-to-consumer advertisements appear to provide valuable information (including risk information); induce information-seeking (mainly from physicians); prompt patients to discuss conditions not previously discussed; and generate significant, positive externalities including the possibility of improved patient compliance with drug therapy. The effects of DTC advertisements on drug consumption and on health care have yet to be assessed. The author suggests that a further relaxation of FDA rules would accelerate the dissemination of valuable information, with favorable consequences for drug development and consumer health.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Timing of new black box warnings and withdrawals for prescription medications
Lasser, K. E. (2002) · JAMA · doi:10.1001/jama.287.17.2215 · Cited by 1,005 · cited 1×
“Also see Lasser, et al., 2002 , for an article in the Journal of the American Medical Association critical of the FDA's safety standards in new drug approval.”
Background
Cited by
Perceived Third‐Person Effects and Consumer Attitudes on Prevetting and Banning DTC Advertising
JISU, H., DELORME, D. E., & REID, L. N. (2006) · Journal of Consumer Affairs · doi:10.1111/j.1745-6606.2006.00047.x · Cited by 165
A content analysis of direct-to-consumer (DTC) prescription drug Web sites
Macias, W., & Lewis, L. S. (2003) · Journal of Advertising · doi:10.1080/00913367.2003.10639147 · Cited by 98
“Recently, the European Union (EU) initiated a limited experiment of DTC advertising by providing information to consumers on treatments for three therapeutic categories (diabetes, AIDS, and asthma) through pamphlets and Web sites only (Calfee 2002).”
BackgroundThe impact of direct-to-consumer television and magazine advertising on antidepressant use
Avery, R. J., Eisenberg, M. D., & Simon, K. I. (2012) · Journal of Health Economics · doi:10.1016/j.jhealeco.2012.05.002 · Cited by 71
“Also supporting this view are arguments that DTCA makes information dissemination more efficient—a virtue in information-intensive markets such as pharmaceuticals (Calfee, 2002).”
BackgroundThe influence of socialization agents on consumer responses to over-the-counter medicine advertising
Lee, M., Kang, M., King, K. W., & Reid, L. N. (2022) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2022.02.001 · Cited by 7
Metadata
- Authors
- Calfee, J. E.
- Venue
- Journal of Public Policy & Marketing
- Publisher
- SAGE Publications
- Published
- 2002-09
- Volume
- 21
- Issue
- 2
- Pages
- 174-193
- ISSN
- 0743-9156 (ISSN-L)
- 1547-7207
- OpenAlex
- W2081255536
- Cited by
- 203
- References
- 1
- FWCI
- 8.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.